[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@CMEINDIA1 Avatar @CMEINDIA1 CME INDIA

CME INDIA posts on X about india, reduce, ada, the first the most. They currently have XXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence countries currencies

Social topic influence india, reduce #999, ada, the first, kolkata #1498, events, threshold, history, built on, strong

Top accounts mentioned or mentioned by @askdrshashank @drsthanus @banshisaboo @omlakhani @singhakendo @kapoornitindr @deepduttaendo @kamleshkhunti @drakhilx @indiaesi @drkhushbooendo @scottisaacsmd @docanoopmisra @rssdiofficial @drambrishmithal @ntfabiano @ecgbuddyarpi @ecgsonly @drmohanv @ecgoxford

Top Social Posts

Top posts by engagements in the last XX hours

"Diagnostic Criteria of DKA (2024 Consensus Update) X Diagnosis of DKA Needs ALL Three Components (A) Hyperglycemia or known diabetes + (B) Ketosis + (C) Metabolic Acidosis Hyperglycemia threshold expanded: XXX mg/dL OR prior history of diabetes irrespective of glucose value. 🔷 X Euglycemic DKA (EDKA): Dont Miss It Seen in XX% of DKA cases. Glucose XXX mg/dL but ketosis + acidosis still present. Common triggers: SGLT2 inhibitors pregnancy fasting insulin overdose alcohol liver failure. SGLT2 inhibitors are now the leading cause worldwide. 🔷 X Ketone Measurement: Beta-Hydroxybutyrate is King"
X Link 2025-12-05T17:46Z 5051 followers, 30.7K engagements

"ADA Standards of Care 2026: The New Algorithm for Glucose-Lowering Therapy in Type X Diabetes The ADA 2026 reinforces a priorities-first approach: X Reduce cardiovascular & kidney (CVKD) risk X Manage weight X Achieve glycemic goals X Address MASLD/MASH risk All built on a foundation of healthy lifestyle + DSMES + addressing SDOH. 🔶 X. FIRST PRIORITY: Cardiovascular & Kidney Risk Reduction A. ASCVD or Indicators of High CV Risk Preferred: GLP-1 RA with proven CV benefit Alternative / Add-on: SGLT2i with proven CV benefit If HbA1c above target combine GLP-1 RA + SGLT2i B. Heart Failure (HFpEF"
X Link 2025-12-09T16:41Z 5051 followers, 14.2K engagements

"ADA Standard of Care in Diabetes 2026 Whats New from ADA Standards of Care 2026 (focusing on clinically important changes): X. Big picture shifts Person-first inclusive language reinforced across all sections. Multiple cross-specialty endorsements strengthened (ACC AGS Obesity Society ASBMR ISPAD NKF etc.) signals strong multisystem multidisciplinary approach. Clear trend: GLP-1 RA / dual GIPGLP-1 RA + SGLT2i + nsMRA at the center of cardio-renal-metabolic care not just glucose control. Technology (CGM + AID systems) pushed much earlier and much broader including T2DM older adults kids"
X Link 2025-12-08T17:24Z 5029 followers, 12.5K engagements

"LDL-C lowering beyond statins is essential Dyslipidaemia: 2025 Update X. Statins remain the unshakable foundation Three decades post-4S statins continue to be the safest most effective and most evidence-backed therapy for reducing ASCVD. Benefit extends across ages even children with genetic dyslipidaemia profit from early statin therapy. X. Statin underutilisation is still a global failure Despite being cheap generic and guideline-recommended statins remain under-prescribed and under-adhered. Real-world practice still lags behind evidence a major modifiable gap in ASCVD prevention. X. LDL-C"
X Link 2025-12-09T10:18Z 5034 followers, 4254 engagements

"One Small Molecule for Man One Giant Leap for Mankind with Obesity Orforglipron & the ATTAIN-1 Trial 🔍 Study Context The ATTAIN-1 trial marks the first completed Phase X trial demonstrating clinically meaningful weight loss with an oral non-peptide small-molecule GLP-1 receptor agonistorforglipronsignaling a paradigm shift in obesity pharmacotherapy. 🌟 Key Clinical Pearls X First-in-class oral small-molecule GLP-1RA Orforglipron is not a peptide Orally bioavailable no injections Targets GLP-1 receptor (GPCR) via small-molecule pharmacology X ATTAIN-1 = a landmark Phase X obesity trial"
X Link 2025-12-13T10:20Z 5051 followers, 1044 engagements

"Abnormal Liver Blood Tests 2025 BMJ Guidance Simplified X Key Principles Before Interpreting Liver Blood Tests Liver blood tests (LBTs) have low sensitivity & specificity abnormal values should trigger evaluation not conclude diagnosis. Do NOT repeat LBTs blindly repeat only after identifying a likely cause. Most abnormal LBTs will NOT normalise in X month avoid early reassessment unless clinical urgency. Interpret LBTs in the entire clinical context (risk factors alcohol intake metabolic status drugs viral risk family history). Prognosis depends on the cause not the magnitude of enzyme"
X Link 2025-12-03T03:57Z 5043 followers, 12.8K engagements

"SGLT2 Inhibitors Modify Fibrosis-4 Index and Mitigate DKD Development: Impact of Background Metformin Therapy X. FIB-4: Beyond the Liver A Surrogate for Kidney Risk FIB-4 (Age AST ALT Platelets) is a validated marker of liver fibrosis but emerging evidence shows it predicts CKD and DKD in people with diabetes. Baseline FIB-4 XXX strongly predicted higher incidence of de novo DKD (new macroalbuminuria or eGFR 60). X. SGLT2i Effects on FIB-4: Benefit Depends on Baseline Risk SGLT2 inhibitors reduced FIB-4 index preferentially in patients who had high FIB-4 at baseline (52% improved vs XX% in"
X Link 2025-12-04T11:56Z 5035 followers, 4395 engagements

"Circadian Rhythm: The Hidden Driver of Gut Health and Disease @AskDrShashank X. GI tract runs on a clockevery organ has its own circadian rhythm Stomach intestine liver pancreas and microbiome possess peripheral clocks synchronized by the central SCN clock. Disruption impaired digestion altered motility dysbiosis inflammation. X. Light is the master timekeeperbut food is the key timer for the gut Light entrains the brain clock. Food timing strongest zeitgeber for GI peripheral clocks. Late eating is a powerful circadian disruptor worsening GERD IBS obesity and metabolic syndrome. X. Clock"
X Link 2025-12-08T04:47Z 5043 followers, 1388 engagements

"🧿 CME INDIA Breaking Clinical Update With inputs from @singhak_endo Retatrutide Phase X Results A New Benchmark in Obesity & OA Knee Management 🔍 Whats New Lillys first Phase X trial (TRIUMPH-4) of Retatrutide the first-in-class triple agonist (GIP + GLP-1 + glucagon) has delivered historic top-line results in obesity with knee osteoarthritis. 🌟 Key Findings (68 Weeks) X Massive Body-Weight Reduction XX mg dose XXXX% body weight XXXX kg weight loss (71.2 lbs) X mg dose XXXX% body weight XXXX kg weight loss This is the largest weight reduction ever reported in a completed Phase X obesity"
X Link 2025-12-11T14:31Z 5045 followers, XXX engagements

"🧿 Oral semaglutide is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients extending cardiovascular protection beyond injectable formulations. SOUL Trial: Oral Semaglutide & Cardiovascular Outcomes in T2DM 🔬 Trial Design SOUL (Semaglutide Cardiovascular Outcomes) trial Randomized double-blind placebo-controlled superiority trial 9650 adults with T2DM High CV risk: ASCVD CKD Intervention: Oral semaglutide up to XX mg daily vs placebo Median follow-up: XXXX months 🌟 Key Clinical Pearls X First oral GLP-1 RA with CV outcomes data Addresses unmet need for cardiovascular"
X Link 2025-12-12T09:59Z 5043 followers, 1208 engagements

"GLP-1 Receptor Agonists & Alcohol-Related Outcomes (2025 Systematic Review & Meta-analysis) (Binayak Sinha & Samit Ghosal Kolkata) 🔍 Key Question Do GLP-1 receptor agonists (GLP-1RAs) reduce alcohol consumption craving or alcohol-related events in adults with or without alcohol use disorder (AUD) 🌟 Clinical Pearls X RCT evidence: trend but not significant GLP-1RAs showed numerical reduction in alcohol intake drinks per drinking day and craving Did not reach statistical significance in current RCTs Indicates underpowered trials / short follow-up X Semaglutide shows a stronger signal"
X Link 2025-12-14T02:34Z 5040 followers, XX engagements

"GLP-1 Receptor Agonists & Alcohol-Related Outcomes (2025 Systematic Review & Meta-analysis) (Binayak Sinha & Samit Ghosal Kolkata) @SAMITGHOSAL @BinayakSinha1 🔍 Key Question Do GLP-1 receptor agonists (GLP-1RAs) reduce alcohol consumption craving or alcohol-related events in adults with or without alcohol use disorder (AUD) 🌟 Clinical Pearls X RCT evidence: trend but not significant GLP-1RAs showed numerical reduction in alcohol intake drinks per drinking day and craving Did not reach statistical significance in current RCTs Indicates underpowered trials / short follow-up X Semaglutide"
X Link 2025-12-14T02:57Z 5051 followers, XXX engagements